Other OTC - Delayed Quote USD

BioCorRx Inc. (BICX)

0.7500 -0.0700 (-8.54%)
At close: April 26 at 11:36 AM EDT
Key Events
Loading Chart for BICX
DELL
  • Previous Close 0.8200
  • Open 1.0200
  • Bid --
  • Ask --
  • Day's Range 0.7500 - 1.0200
  • 52 Week Range 0.6720 - 2.2200
  • Volume 902
  • Avg. Volume 1,053
  • Market Cap (intraday) 6.612M
  • Beta (5Y Monthly) 0.57
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4500
  • Earnings Date May 13, 2024 - May 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

www.biocorrx.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BICX

Performance Overview: BICX

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BICX
3.85%
S&P 500
6.92%

1-Year Return

BICX
61.93%
S&P 500
25.26%

3-Year Return

BICX
71.26%
S&P 500
22.00%

5-Year Return

BICX
85.71%
S&P 500
74.29%

Compare To: BICX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BICX

Valuation Measures

Annual
As of 4/29/2024
  • Market Cap

    6.61M

  • Enterprise Value

    8.38M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    70.19

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    93.99

  • Enterprise Value/EBITDA

    -3.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -404.57%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    89.16k

  • Net Income Avi to Common (ttm)

    -3.77M

  • Diluted EPS (ttm)

    -0.4500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    65.22k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -883.08k

Research Analysis: BICX

Company Insights: BICX

Research Reports: BICX

People Also Watch